【レポートの概要（一部）】
1. Report Overview
1.1 Global Translational Regenerative Medicine: Market Overview
1.2 Global Translational Regenerative Medicine Market Definition and Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered By This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. An Introduction To Translational Regenerative Medicine
2.1 What Is Regenerative Medicine?
2.1.1 Translational Regenerative Medicine – From Bench to Bedside
2.2 Translational Regenerative Medicine – Market Breakdown
2.2.1 Stem Cell Therapy – Marketable Differentiation And Specialisation
2.2.1.1 How Embryonic Stem Cells (ESCs) Entered The Fray
2.2.1.2 Classifying Stem Cells by Potency
2.2.1.3 Stem Cells Categories: ESCs, SSCs, iPSCs
2.2.1.4 Parthenogenetic Stem Cells: Ethical ESC-Like Cells?
2.2.1.5 Autologous vs. Allogeneic Stem Cells: Towards Universal Stem Cell Products?
2.2.2 Tissue Engineering – In Vitro Manipulation for Therapeutic Purposes
2.2.3 Gene Therapies
2.2.3.1 Harnessing Infectivity: Viral Vectors in Gene Therapy
2.3 Other Approaches to Regenerative Medicine
2.3.1 Small Molecules and Proteins – Scaffold-Based Delivery of Signalling Molecules
2.3.2 Cosmetic Applications of Regenerative Medicine
2.4 Regulation of Regenerative Medicine
2.4.1 Regulation of Regenerative Medicine Products in Europe
2.4.2 Regulation of Regenerative Medicine Products in the US
2.5 The Phases of Clinical Trials
2.6 Market Definition
2.6.1 Products Excluded from the Report
3. Translational Regenerative Medicine Market, 2016-2026
3.1 Global Translational Regenerative Medicine: Market Overview
3.1.1 Segments within the Global Translational Regenerative Medicine Market
3.2 The Global Translational Regenerative Medicine Market in 2014 and 2015
3.3 Global Translational Regenerative Medicine: Market Forecast 2016-2026
3.3.1 Market Sectors That Will Drive Translational Regenerative Medicine Growth
3.3.2 Global Translational Regenerative Medicine Market – Changing Market Shares By Sector 2016-2026
4. Stem Cell Therapies: Leading Applications, 2016-2026
4.1 The Global Market for Stem Cell Therapies, 2014 and 2015
4.1.1 Stem Cell Therapies: Currently Available Therapies
4.1.2 Haematopoietic Stem Cell Transplantation (HSCT)
4.1.2.1 HSCT for the Treatment of Multiple Sclerosis – A Possible Cure?
4.1.3 Stem Cell Orthobiologics
4.2 Stem Cell Therapies: Global Market Forecast 2016-2026
4.3 AlloStem (AlloSource)
4.4 Osteocel Plus (NuVasive)
4.4.1 Osteocel Plus: Sales Forecast 2016-2026
4.5 Trinity ELITE and Trinity Evolution (Orthofix)
4.5.1 Trinity ELITE and Trinity Evolution: Sales Forecast, 2016-2026
4.6 PureGen (AlphaTec Spine)
4.7 Other Approved Stem Cell Therapy Products, 2015
4.7.1 Cartistem (Medipost)
4.7.2 Cupistem (Anterogen)
4.7.3 Hearticellgram-AMI (Pharmicell)
4.7.4 TEMCELL/ Prochymal/ Remestemcel-L (Mesoblast)
4.7.4.1 TEMCELL/ Prochymal (Remestemcel-L): Sales Forecast 2016-2026
4.8 Development Pipeline for Stem Cell Therapies, 2016-2026
4.8.1 Late-Stage Pipeline for Stem Cell Therapies, 2015
4.8.1.1 StemEx and NiCord (Gamida Cell)
4.8.1.1.1 StemEx Shows Improved Survival at 100 Days – but FDA Wants Another Clinical Trial
4.8.1.2 Copper Chelator Based Technology
4.8.1.3 NiCord
4.8.1.3.1 NiCord: Gamida Cell Reaches Agreement on Phase 3 Design Outline with the FDA and EMA
4.8.1.3.2 NAM Technology Platform
4.8.1.4 Mesenchymal Precursor Cell Therapies (Mesoblast)
4.8.1.5 Adult Autologous CD34+ Cells (Baxter)
4.8.1.6 MyoCell (U.S. Stem Cell Inc.)
4.8.1.7 Cx601 (TiGenix)
4.8.1.8 Adipose-Derived Stem Cells (Cytori Therapeutics)
4.8.1.9 Stempeucel (Stempeutics Research)
4.8.1.10 C-Cure (Cardio3 BioSciences)
4.8.1.11 Other Late-Stage Stem Cell Therapies
4.8.2 Diabetes and Stem Cell Therapy
4.8.2.1 Mesenchymal Precursor Cells (Mesoblast)
4.8.2.2 VC-01 (ViaCyte Inc)
4.8.2.2.1 Clinical Development Efforts for VC-01 for the Treatment of Diabetes
4.8.3 Cardiovascular Disease and Stem Cell Therapy
4.8.3.1 Endometrial Regenerative Cells (MediStem, Intrexon)
4.8.3.2 AMR-001 (Caladrius Biosciences)
4.8.3.3 CAP-1002 (Capricor)
4.8.4 Stem Cell Therapy in Cancer
4.8.4.1 CLT-008 (Cellerant Therapeutics)
4.8.4.2 OncoCyte/BioTime – Targeting Cancer with Gene and Stem Cell Therapy
4.8.5 Stem Cell Therapy for Central Nervous System (CNS) Conditions
4.8.5.1 NurOwn (BrainStorm Cell Therapeutics)
4.8.5.1.1 Clinical Development Efforts for NurOwn, 2015
4.8.5.2 NSI-566 (Neuralstem)
4.8.5.3 NSI-189 (Neuralstem)
4.8.5.4 MultiStem (Athersys)
4.8.5.5 PDA-001 (Cenplacel-L, Celgene)
4.8.5.6 ALD-401 (Cytomedix)
4.8.5.7 ReN001 (ReNeuron)
4.8.6 Stem Cell Therapy for Eye Diseases
4.8.6.1 MA09-hRPE (Ocata Therapeutics)
4.8.6.2 HuCNS-SC (StemCells Inc.)
4.8.6.3 Collaboration And License Agreement Between Pfizer And The London Project to Cure Blindness
4.9 Stem Cells Therapy Market: Drivers and Restraints 2016-2026
5. Tissue Engineering Therapies: Leading Applications, 2016-2026
5.1 The Global Market for Tissue Engineered Therapies, 2014 and 2015
5.1.1 Tissue Engineering Therapies: Currently Available Therapies
5.2 Tissue Engineering Therapies: Global Market Forecast 2016-2026
5.3 Tissue Engineering in Wound Repair and Healing
5.3.1 Apligraf (Organogenesis)
5.3.1.1 Apligraf: Historical Sales Analysis
5.3.1.2 Apligraf: Sales Forecast 2016-2026
5.3.2 BioDfence and BioDfactor (BioD)
5.3.3 CureXcell (MacroCure)
5.3.4 Dermagraft (Organogenesis)
5.3.4.1 Dermagraft (Organogenesis): Sales Forecast 2016-2026
5.3.5 Epicel (Vericel)
5.3.6 Grafix (Osiris Therapeutics)
5.3.7 MySkin and CyroSkin (Regenerys)
5.3.8 ReCell (Avita Medical)
5.3.8.1 ReCell (Avita Medical): Sales Forecast 2016-2026
5.4 Tissue Engineering for Cartilage Repair
5.4.1 Autologous Chondrocyte Implantation (ACI)
5.4.2 Carticel (Vericel Corp.)
5.4.3 ChondroCelect (TiGenix, Sobi Partners)
5.4.4 DeNovo NT (Zimmer)
5.4.5 MACI (Vericel Corp.)
5.5 Other Available Tissue Engineering Therapies
5.5.1 Autologous Cultured Cell and Tissue Products (Japan Tissue Engineering Co.)
5.5.2 Gintuit (Organogenesis)
5.5.3 LAVIV (azficel-T), (Fibrocell Science)
5.5.4 Acellular Tissue Engineering Products
5.6 Tissue Engineering: Development Pipeline, 2016-2026
5.6.1 Pipeline Products for Autologous Chondrocyte Implantation
5.6.2 Tissue Engineering for Skin
5.6.3 Tissue Engineering for Liver Diseases
5.6.3.1 Extracorporeal Bio-Artificial Liver Therapy (Vital Therapies)
5.6.4 Tissue Engineering for Cardiovascular Disease
5.6.5 Tissue Engineering for Eye Diseases
5.7 Future Prospects for Organ Transplantation and Tissue Engineering
5.8 Tissue Engineered Products Market: Drivers and Restraints 2016-2026
6. Gene Therapies: Leading Applications, 2016-2026
6.1 The Global Market for Gene Therapies, 2014 and 2015
6.2 Gene Therapies: Global Market Forecast 2016-2026
6.3 Currently Available Gene Therapy Products
6.3.1 Gendicine (Benda Pharmaceutical)
6.3.2 Oncorine (Shanghai Sunway Biotech)
6.3.3 Neovasculgen (Human Stem Cells Institute)
6.3.3.1 Neovasculgen (HSCI): Sales Forecast 2016-2026
6.3.4 Glybera (UniQure)
6.3.4.1 Glybera: Sales Forecast 2016-2026
6.4.1.4 IMLYGIC (talimogene laherparepvec) – (Amgen)
6.4.1.4.1 Clinical Trials and Development Efforts for IMLYGIC
6.4.1.4.2 Talimogene Laherparepvec (IMLYGIC) – Sales Forecast 2016-2026
6.4 Development Pipeline For Gene Therapies, 2016-2026
6.4.1 Late-Stage Pipeline Gene Therapies, 2015
6.4.1.1 Collategene (beperminogene perplasmid, AMG0001) – (AnGes MG/Vical)
6.4.1.2 ProstAtak (AdV-tk) – (Advantagene)
6.4.1.3 Trinam (taberminogene vadenovec) – (Ark Therapeutics)
6.4.1.4 AAV2-hRPE65v2 (Spark Therapeutics)
6.4.1.5 CG0070 (Cold Genesys)
6.4.2 Gene Therapy for Use in the Treatment of Diabetes
6.4.3 Gene Therapy Directed At Oncology Indications
6.4.4 Gene Therapy Directed at Neurological Diseases
6.4.5 Gene Therapy Directed at Tackling Haemophilia B
6.5 Gene Therapy Market: Drivers and Restraints 2016-2026
7. Leading National Markets for Translational Regenerative Medicine, 2016-2026
7.1 The Translational Regenerative Medicine Market by Region
7.1.1 The Global Distribution of Translational Regenerative Medicine in 2014 and 2015
7.2 Leading National Markets: Forecast 2016-2026
7.2.1 Changing Market Shares By Region, 2016-2026
7.3 Regional Translational Regenerative Medicine Markets: Analysis and Forecasts, 2016-2026
7.4 United States: The Largest Translational Regenerative Medicine Market
7.4.1 US Translational Regenerative Medicine Market: Market Drivers and Restraints, 2016-2026
7.4.2 US Translational Regenerative Medicine Market: Market Forecast 2016-2026
7.4.3 The Regulatory Framework for Regenerative Medicine in the US
7.4.4 The Impact of Ethical and Regulatory Reluctance to Embryonic Stem Cell Research and Its Impact on Funding
7.4.5 How Is the Ending of Patenting for Human Gene Products Affecting the Regenerative Medicine Market in the US?
7.5 Europe: A Fragmented Regenerative Medicine Market
7.5.1 European Regenerative Medicine Market: Market Drivers and Restraints, 2016-2026
7.5.2 European Regenerative Medicine Market: Market Forecast 2016-2026
7.5.3 Europe’s Unitary Patent System and Its Impact on the Future of Regenerative Medicine in the Region
7.5.4 Regulation of Regenerative Medicine in the European Union
7.5.5 UK: A Leading Research Centre for Regenerative Medicine in Europe
7.5.5.1 Regulation of Stem Cell Research in the UK
7.5.6 Russia: Rising Interest in Regenerative Medicine Research
7.6 Asia-Pacific: Accommodating Regulatory Landscape Aiding Rapid Product Commercialisation
7.6.1 Asia-Pacific Regenerative Medicine Market: Market Drivers and Restraints, 2016-2026
7.6.2 Asia-Pacific Regenerative Medicine Market: Market Forecast 2016-2026
7.6.3 Australia: Encouraging Translational Regenerative Medicine
7.6.4 China: Encouraging Stem Cell R&D
7.6.4.1 Government Intervention into TRM Research in China
7.6.4.2 Regulation of Stem Cell Research in China
7.6.4.3 Commercialisation of Gene Therapy and Tissue Engineering Products in China
7.6.4.4 Medical Tourism Impacting Market Growth for Regenerative Medicine in China
7.6.5 Japan: Difficulty in Translating Research into Commercialisation
7.6.5.1 Research Funding: A Major Determinant of Growth in Japan’s Regenerative Medicine
7.6.5.2 Government Interventions in Promoting Stem Cell Research in Japan
7.6.5.3 Regulation of Regenerative Medicine in Japan
7.6.5.4 Accelerating Approvals of Regenerative Medicine Products in Japan
7.6.6 India: An Emerging Market for Regenerative Medicine
7.6.6.1 Efforts in Stem Cell Research in India
7.6.6.2 Unclear Guidelines Hindering Progression of Gene Therapy Research in India
7.6.7 South Korea: First to Approve Stem Cell Treatments
7.6.7.1 A Regeneration In South Korea’s Stem Cell Research Efforts
7.7 Rest of the World: Regenerative Medicine Conquering New Territories and Booming
7.7.1 Rest of the World Regenerative Medicine Market: Market Forecast 2016-2026
8. The Leading Companies in the the Translational Regenerative Medicine Market, 2016-2026
8.1 Translational Regenerative Medicine: A Hotbed for Innovation
8.2 Alphatec Spine
8.2.1 Alphatec Spine: Financial and Performance Analysis, 2009-2014
8.2.2 Alphatec Spine’s Shifting Focus from Regenerative Medicine to Medical Devices
8.3 Anterogen
8.3.1 Anterogen: Pipeline Analysis, 2015
8.4 Athersys
8.4.1 Athersys: Financial and Performance Analysis, 2010-2014
8.4.2 Athersys: Pipeline Analysis, 2015
8.4.2.1 MultiStem Technology – Potential Treatment for a Range of Diseases
8.5 Avita Medical
8.5.1 Avita Medical: Historical Financial and Performance Analysis, 2013-2015
8.5.2 Avita Medical: Regenerative Medicine Portfolio, 2015
8.5.3 Avita Medical: Pipeline Analysis, 2015
8.6 AxoGen
8.6.1 AxoGen: Historical Financial and Performance Analysis, 2010-2014
8.6.2 AxoGen: Regenerative Medicine Portfolio, 2015
8.6.3 AxoGen: Pipeline Analysis, 2015
8.8 Medipost
8.7.1 Medipost: Historical Financial and Performance Analysis, 2010-2014
8.7.2 Medipost: Regenerative Medicine Portfolio, 2015
8.7.3 Medipost: Pipeline Analysis, 2015
8.8 Mesoblast
8.8.1 Mesoblast Product Portfolio, 2015
8.8.2 Mesoblast: Historical Financial and Performance Analysis, 2010-2015
8.8.3 Mesoblast: Pipeline Analysis, 2015
8.8.3.1 NeoFuse
8.8.3.2 Chondrogen
8.8.3.3 Prochymal / TEMCELL
8.8.3.4 Other Recent Pipeline Acquisitions by Mesoblast
8.9 NuVasive
8.9.1 NuVasive Product Portfolio, 2015
8.9.2 NuVasive: Historical Financial and Performance Analysis, 2009-2013
8.9.3 NuVasive: Pipeline Analysis, 2015
8.10 Ocata Therapeutics
8.10.1 Ocata Therapeutics: Historical Financial and Performance Analysis, 2009-2014
8.10.2 Ocata Therapeutics: Pipeline Analysis, 2015
8.10.2.1 Retinal Pigment Epithelial Cell Therapy
8.10.3 Ocata’s Other Therapeutic Platforms
8.11 Organogenesis
8.11.1 Organogenesis RM Portfolio, 2015
8.11.2 Organogenesis: Pipeline Analysis, 2015
8.12 Osiris Therapeutics
8.12.1 Osiris Therapeutics: RM Portfolio, 2015
8.12.2 Osiris Therapeutics: Historical Financial and Performance Analysis, 2010-2014
8.12.3 Osiris Therapeutics: Pipeline Analysis, 2015
8.13 Pharmicell
8.13.1 Pharmicell: Historical Financial and Performance Analysis, 2010-2014
8.13.2 Pharmicell: Pipeline Analysis, 2015
8.14 Regenerys
8.14.1 Regenerys: RM Portfolio, 2015
8.14.2 Regenerys: Pipeline Analysis, 2015
8.15 TiGenix
8.15.1 TiGenix: Historical Financial and Performance Analysis, 2011-2014
8.15.2 TiGenix: Pipeline Analysis, 2015
8.16 UniQure
8.16.1 UniQure: Pipeline Analysis, 2015
8.17 Vericel Corporation (Formerly Aastrom Biosciences, Inc.)
9. Qualitative Analysis of the Translational Regenerative Medicine Market, 2015
9.1 Market Factors Influencing the Translational Regenerative Medicine Market
9.2 SWOT Analysis of the Translational Regenerative Medicine Market, 2016-2026
9.3 Strengths
9.3.1 Improvements in Regulatory Frameworks
9.3.2 Advancements in General Cellular and Tissue Research Aiding Regenerative Medicine
9.3.3 Strong Support from Governments in Multiple Regions
9.3.4 Increasing Ease of Product Commercialisation and Market Access
9.4 Weaknesses
9.4.1 The High Price of Translational Regenerative Medicine Products May Restrain Market Growth
9.4.2 Lack of Funding from Venture Capital
9.4.3 The Intrinsic Lack of Standardisation is a Burden to Scaling up Manufacturing
9.4.4 Successful Commercialisation of TRM Products Requires New Business Models
9.5 Opportunities
9.5.1 3D Bioprinting and Other Technologies May Enable Rapid Scale-Up
9.5.2 Medical Tourism May Stimulate Standardisation and Drive Market Growth
9.5.3 Disruptive Translational Regenerative Medicine Therapies Can Create New Markets
9.6 Threats
9.6.1 Ethical Concerns Limiting R&D in Regenerative Medicine
9.6.2 Difficulty Establishing an Evidence Base For Long-Term Efficacy Of TRM Therapies
9.6.3 Rate of Scientific Progress – A Major Determinant of TRM Market Growth
9.6.4 Restraints on Reimbursement May Slow Growth
9.7 Porter’s Five Force Analysis of the Translational Regenerative Medicine Market, 2016-2026
9.7.1 Threat of New Entrants
9.7.2 Threat of Substitutes
9.7.3 Power of Suppliers
9.7.4 Power of Buyers
9.6.5 Rivalry among Competitors
10. Research Interviews
10.1 Interview with Dr Cynthia Bamdad, PhD, CEO of Minerva Biotechnologies
10.1.1 Naïve State Stem Cells Could Significantly Impact the Regenerative Medicine Market
10.1.2 On Relationships between Big Pharma and Smaller Biotech Companies in the Translational Regenerative Market
10.1.3 Growth of Minerva Biotechnologies
10.1.4 Possible New Commercial Applications for Regenerative Medicine
10.1.5 Translational Regenerative Medicine in Emerging Markets
10.1.6 iPS Cells – The Future of Stem Cell Therapies?
10.1.7 On Drivers and Restraints in the Translational Regenarative Medicine Market in 2016
10.2 Interview with Dr Yael Margolin, CEO of Gamida Cell Ltd.
10.2.1 Progress of NiCord in the Blood Cancer Indication
10.2.2 On Drivers and Restraints in the Blood Cancer Market in 2015
10.2.3 Growth of Gamida Cell Ltd.
11. Conclusion
11.1 Overview of Current Market Conditions and Market Forecast, 2014-2026
11.2 Leading Regenerative Medicine Segments in 2014 and 2015
11.3 Leading Regions in the Translational Regenerative Medicine Market in 2014 And 2015
11.4 Future Outlook for the Various Sectors within TRM, 2016-2026
11.5 R&D Pipeline Products Crucial to Future Market Growth
11.6 What Does the Future Hold for Regenerative Medicine?
12. Glossary
Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
【レポート販売概要】
■ タイトル：展開再生医療の世界市場展望：幹細胞治療、組織工学、遺伝子治療■ 英文：Translational Regenerative Medicine: Market Prospects 2016-2026
■ 発行日：2016年1月
■ 調査会社：visiongain
■ 商品コード：VGAIN6022519
■ 調査対象地域：グローバル
- グローバルにおける液体ポンプおよび液体エレベーター市場（～2019）The industry report Global Liquid Pump and Elevator Market to 2019 - Market Size, Development, and Forecasts offers the most up-to-date market data on the actual market situation, and future outlook for liquid pumps and elevators in the world. The research includes historic market data from 2008 to 2014 and forecasts until 2019 which makes the report an invaluable resource for industry executives, …
- ヘルスケア産業におけるビックデータ市場2015 – 2020The global healthcare industry faces three key challenges. First is the requirement for cost reduction without jeopardizing the quality and management of healthcare services for everyone. The second challenge involves the significant increase in healthcare concerns, ranging from rising rate of chronic diseases, aging population and the dynamic consumer demands, including accessibility and health c …
- 免疫グロブリン（Ig）製品の世界市場2016-2020About Immunoglobulin Products Immunoglobulins, also known as antibodies, are proteins that help neutralize foreign objects such as bacteria and viruses. They help recognize and bind to particular antigens. Based on the difference in the amino acid sequence in the fragment crystallizable (Fc) region of the antibody heavy chain, they can be categorized into the following isotypes: IgA, IgD, IgE, IgG …
- クリーンラベル成分の世界市場：種類別（自然色、天然香料、デンプン＆甘味料、天然防腐剤、その他）、用途別（飲料、ベーカリー＆菓子、ソース＆調味料、乳製品＆冷凍デザート、その他の加工食品）、フォーム別（粉末、液体）The clean label ingredients market was valued at $38.8 billion in 2018, and is projected to reach $64.1 billion by 2026, growing at a CAGR of 6.8% from 2019 to 2026. Clean label products are those which are made by using very few ingredients and are natural or organic. Although organic farming is old term, clean label ingredients is a new trend in the food & beverage industry. Clean label does not …
- 世界の方向性電磁鋼板市場2015The Global Grain Oriented Electrical Steel Industry Report 2015 is a professional and in-depth study on the current state of the Grain Oriented Electrical Steel industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Grain Oriented Electrical Steel market analysis is provided for the international markets …
- 可変周波数駆動(VFD)の世界市場2019-2023Technavio Announces the Publication of its Research Report – Global Variable Frequency Drives (VFD) Market 2019-2023 Technavio recognizes the following companies as the key players in the global variable frequency drives (VFD) market: ABB, Danfoss, Rockwell Automation Inc., Schneider Electric, Siemens. Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momen …
- 逆浸透法（RO）装置の世界市場2017-2021About Reverse Osmosis (Ro) SystemsRO is a technology that uses a semi-permeable membrane to remove dissolved salts or organic molecules from water. The water is pushed under pressure through the membrane, which allows the passage of water molecules but prevents the dissolved salts and bacteria from passing through. Technavio’s analysts forecast the global reverse osmosis (Ro) systems market to gro …
- Duke Energy Corporation：発電所及びSWOT分析2013Duke Energy Corporation - Power Plants and SWOT Analysis, 2013 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executives), and major products and services. Scope - Major Power Plants (assets) - summarized …
- 脊髄ポンプの世界市場分析：用途別（痙攣管理、疼痛管理、非悪性疼痛、悪性疼痛）、セグメント予測The global spinal pumps market is expected to reach USD 319.8 million by 2024, according to a new report by Grand View Research, Inc. The rising geriatric population base, which is highly susceptible to developing chronic disorders, such as cancer as well as movement and neurological disorders, leading frequently to subsequent spasms and pain, is presumed to propel the need for spinal pumps. Accor …
- 合法的傍受の世界市場：傍受デバイス、傍受サービス、通信内容、ネットワーク技術About Lawful Interception Cyber threats are internet-based attempts aimed at disrupting or damaging IT systems of enterprises and hack critical information. Lawful interception refers to legally authorized surveillance of data and voice communication; it constitutes an important tool for law enforcement agencies worldwide for investigating and litigating criminal activities and tackle the ever-gro …
- 世界の生化学アナライザー市場動向（2012-2016）TechNavio's analysts forecast the Global Biochemistry Analyzers market to grow at a CAGR of 4.50 percent over the period 2012-2016. One of the key factors contributing to this market growth is the advancements in technology. The Global Biochemistry Analyzers market has also been witnessing the increase in technological innovations. However, the negative impact of global recession could pose a chal …
- 鋸刃の世界市場2016-2020About Saw Blades A saw is primarily used to cut through materials such as wood, metal, stone, and concrete. It consists of a blade, chain, or toothed edge that enables smooth cutting operation and is termed as saw blade. Some of the commonly used saw blades are stone cutting, circular, band, hand, chain, and straight saw blades. These saw blades have varying designs based on the required strength …
- 体外膜酸素化装置の世界市場：治療法別、地域別Global Extracorporeal Membrane Oxygenation Machines Market: About this market Technavio’s extracorporeal membrane oxygenation machines market analysis considers sales from veno-venous and arterio-venous; and veno-arterial modalities. Our study also finds the sales of extracorporeal membrane oxygenation machines in Asia, Europe, North America, and ROW. In 2019, the veno-venous and arterio-venous se …
- 定置洗浄（CIP）の世界市場予測（～2023年）“Clean-in-place market is expected to grow at CAGR of 15.49% from 2018 to 2023” The clean-in-place market is expected to grow from USD 7.5 billion in 2018 to USD 15.4 billion by 2023, at a CAGR of 15.49%. The growth of this market is mainly driven by several factors, such as advantages of CIP systems in various applications, increased use of CIP systems in the pharma industry, and high demand for …
- 3Dコンクリート・プリンティングの世界市場予測（～2021）MarketsandMarkets projects that the 3D concrete printing market size will grow from USD 24.5 Million in 2015 to reach USD 56.4 Million by 2021, at an estimated CAGR of 15.02%. The implementation of 3D concrete printing technologies is an important strategy taken up by many construction companies and regulatory bodies in recent years. The 3D concrete printing market has been growing in accordance w …
